End-stage rheumatoid arthritis: specific features of patient management
https://doi.org/10.14412/1996-7012-2013-2385
Abstract
The paper provides data on the treatment of patients with end-stage rheumatoid arthritis (RA) and a rationale for the long-term treatment with disease-modifying antirheumatic drugs, including leflunomide as a first-line agent. It describes a clinical case of a patient with end-stage RA during arava treatment.
References
1. <div><p>World Health Organization. The burden of musculoskeletal conditions at the start of the new millennium. Available at: http://whqlib-doc.who.int/trs/WHO_TRS_919.pdf.</p><p>Насонов Е.Л., Насонова В.А. Ревматология. Национальное руководство. М.: ГЭОТАР-Медиа, 2010;720 с.</p><p>Gaujoux-Viala C., Smolen J., Landewe R. et al. Ann Rheum Dis 2010;69:1004-9.</p><p>Насонова В.А., Насонов Е.Л., Алекперов Р.Т. и др. Рациональная фармакотерапия ревматических заболеваний: руководство для практикующих врачей. М.: Литтерра, 2003;507 с.</p><p>Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61(4):290—7.</p><p>Stuhlmeier K. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide. J Immunol 2005;174(11):7376—82.</p><p>Rückemann K., Fairbanks L., Carrey E.A. et al. Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans. J Biol Chem 1998;273(34):21682—91.</p><p>Silva H., Cao W., Shorthouse R. et al. In vitro and in vivo effects of leflunomide, Brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc 1997;29(1-2):1292-3.</p><p>Scott D.L., Schattenkirchner M., Smolen J.S. et al. Efficacy of leflunomide vs placebo vs sulfasalazine in rheumatoid arthritis: effect of disease duration. Arthr Rheum 1998;41:155.</p><p>Grisar J., Aringer M., Köller M. et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells Ann Rheum Dis 2004;63:1632-7.</p><p>Li E., Tam L., Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004;26(4):447-59.</p><p>Dougados M., Emery P., Lemmel E. et al. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis 2005;64:44-51.</p><p>Cohen S., Cannon G.W., Schiff M. et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthr Rheum 2001;44(9):1984—92.</p></div><br />
Review
For citations:
Shostak NA, Klimenko AA. End-stage rheumatoid arthritis: specific features of patient management. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(2):66-70. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2385
Views:
2402
Email this article 